keyword
MENU ▼
Read by QxMD icon Read
search

quetiapine metabolic

keyword
https://www.readbyqxmd.com/read/27871720/-guidelines-for-the-prescription-of-mood-stabilizers-for-adolescents-a-literature-review
#1
G Munch, N Godart
INTRODUCTION: Adolescence is a unique phase of the human developmental process. In adolescents, psychotropic medications may have different efficacy and tolerance profiles compared to those at other stages of the lifespan. Mood stabilizers are a complex pharmacological category including lithium, some anticonvulsants, and some second generation antipsychotics. Focusing on this class of pharmacological agents, we aim to answer the following questions: in which indications and according to which modalities should mood stabilizers be prescribed during adolescence? METHODS: Information was sought from the websites of the French Haute Autorité de santé (HAS) and Agence nationale de sécurité du médicament et des produits de santé (ANSM), the American Food and Drug Administration (FDA) and the British National Institute for Health and Clinical Excellence (NICE)...
November 18, 2016: L'Encéphale
https://www.readbyqxmd.com/read/27803466/comparative-physicochemical-and-pharmacokinetic-properties-of-quetiapine-and-its-active-metabolite-norquetiapine
#2
Dong-Wook Kim, Kwon-Yeon Weon, Eon-Pyo Hong, Eun Kyoung Chung, Kyung-Tae Lee
Quetiapine (QTP) is an atypical antipsychotic drug commonly used to treat several psychiatric disorders and is metabolized into the active metabolite norquetiapine (NQTP). This study was designed to evaluate and compare the physicochemical properties, metabolic stability, brain distribution, and pharmacokinetics of QTP and NQTP. Compared to QTP, NQTP had a higher pKa, solubility, and rat liver microsomal stability, optimal log D and similar log P values. For pharmacokinetic evaluation, QTP and NQTP were administered orally and intravenously to rats at various doses...
2016: Chemical & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/27776389/arterial-stiffness-in-patients-taking-second-generation-antipsychotics
#3
Ebru Fındıklı, Mustafa Gökçe, Vedat Nacitarhan, Mehmet Akif Camkurt, Hüseyin Avni Fındıklı, Selçuk Kardaş, Merve Coşgun Şahin, Mehmet Fatih Karaaslan
Objective: That treatment with second-generation antipsychotics (SGAs) causes metabolic side effects and atherosclerosis in patients with schizophrenia and bipolar disorder (BD) is well-known. Increased arterial stiffness is an important marker of arteriosclerosis and has been identified as an independent risk factor for cardiovascular diseases. We measured pulse wave velocity (PWV) as a marker of arteriosclerosis in patients with schizophrenia and BD who use SGAs. Methods: Patients and controls were collected from our psychiatry outpatient clinics or family medicine...
November 30, 2016: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27620899/incidence-of-non-alcoholic-fatty-liver-disease-and-metabolic-dysfunction-in-first-episode-schizophrenia-and-related-psychotic-disorders-a-3-year-prospective-randomized-interventional-study
#4
María José Morlán-Coarasa, María Teresa Arias-Loste, Víctor Ortiz-García de la Foz, Obdulia Martínez-García, Carmen Alonso-Martín, Javier Crespo, Manuel Romero-Gómez, Emilio Fábrega, Benedicto Crespo-Facorro
RATIONALE: Patients with schizophrenia spectrum disorders have increased morbidity and mortality, largely due to cardiovascular disease, which is associated with antipsychotic treatment. OBJECTIVES: Because of the link between cardiometabolic risk, non-alcoholic fatty liver disease (NAFLD), and antipsychotics, we aimed to investigate the development of NAFLD during the first 3 years of antipsychotic treatment in first episode non-affective psychosis patients. RESULTS: A sample of 191 subjects was included in final analyses, randomly assigned to aripiprazole (N = 83), risperidone (N = 12), quetiapine (N = 46), and ziprasidone (N = 50)...
September 12, 2016: Psychopharmacology
https://www.readbyqxmd.com/read/27483368/adverse-renal-endocrine-hepatic-and-metabolic-events-during-maintenance-mood-stabilizer-treatment-for-bipolar-disorder-a-population-based-cohort-study
#5
Joseph F Hayes, Louise Marston, Kate Walters, John R Geddes, Michael King, David P J Osborn
BACKGROUND: There is limited, poorly characterized information about adverse events occurring during maintenance treatment of bipolar disorder. We aimed to determine adverse event rates during treatment with lithium, valproate, olanzapine, and quetiapine. METHODS AND FINDINGS: We conducted a propensity score adjusted cohort study using nationally representative United Kingdom electronic health records from January 1, 1995, until December 31, 2013. We included patients who had a diagnosis of bipolar disorder and were prescribed lithium (n = 2148), valproate (n = 1670), olanzapine (n = 1477), or quetiapine (n = 1376) as maintenance mood stabilizer treatment...
August 2016: PLoS Medicine
https://www.readbyqxmd.com/read/27466220/baseline-perfusion-alterations-due-to-acute-application-of-quetiapine-and-pramipexole-in-healthy-adults
#6
Lars Michels, Sigrid Scherpiet, Philipp Stämpfli, Uwe Herwig, Annette B Brühl
BACKGROUND: The dopaminergic system is implicated in many mental processes and neuropsychiatric disorders. Pharmacologically, drugs with dopamine receptor antagonistic and agonistic effects are used, but their effects on functional brain metabolism are not well known. METHODS: In this randomized cross-over, placebo-controlled and rater-blinded study, 25 healthy adults received an acute dose placebo substance (starch), quetiapine (dopamine receptor antagonist), or pramipexole (dopamine agonist of the non-ergoline class) 1 hour before the experiment...
July 27, 2016: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27347638/an-update-of-safety-of-clinically-used-atypical-antipsychotics
#7
L Orsolini, C Tomasetti, A Valchera, R Vecchiotti, I Matarazzo, F Vellante, F Iasevoli, E F Buonaguro, M Fornaro, A L C Fiengo, G Martinotti, M Mazza, G Perna, A Carano, A De Bartolomeis, M Di Giannantonio, D De Berardis
INTRODUCTION: The atypical antipsychotic (APs) drugs have become the most widely used agents to treat a variety of psychoses because of their superiority with regard to safety and tolerability profile compared to conventional/'typical' APs. AREAS COVERED: We aimed at providing a synthesis of most current evidence about the safety and tolerability profile of the most clinically used atypical APs so far marketed. Qualitative synthesis followed an electronic search made inquiring of the following databases: MEDLINE, Embase, PsycINFO and the Cochrane Library from inception until January 2016, combining free terms and MESH headings for the topics of psychiatric disorders and all atypical APs as following: ((safety OR adverse events OR side effects) AND (aripiprazole OR asenapine OR quetiapine OR olanzapine OR risperidone OR paliperidone OR ziprasidone OR lurasidone OR clozapine OR amisulpride OR iloperidone))...
October 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27222264/current-trends-on-antipsychotics-focus-on-asenapine
#8
REVIEW
Donatella Marazziti, Armando Piccinni, Stefano Baroni, Francesco Mungai, Silvio Presta, Federico Mucci, Liliana Dell'Osso
Over the years, both first- (FGAs) and second-generation antipsychotics (SGAs), continue to gain increasing evidence of being effective in the treatment of psychotic symptoms. Currently, they represent the first-line treatment of schizophrenia and bipolar disorder, although they are widely used in psychotic depression and other clinical conditions, such as agitation and/or behavioural disturbances. Despite representing an indispensable tool for the treatment of severe psychotic disorders, they are widely known to have a number of unwanted side effects that the clinician must be aware of, and handle carefully to provide the patient the best available treatment in the short and long-term...
2016: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/27209421/the-effects-of-antipsychotics-on-weight-gain-weight-related-hormones-and-homocysteine-in-children-and-adolescents-a-1-year-follow-up-study
#9
Inmaculada Baeza, Laura Vigo, Elena de la Serna, Rosa Calvo-Escalona, Jessica Merchán-Naranjo, Pamela Rodríguez-Latorre, Celso Arango, Josefina Castro-Fornieles
To analyze weight gain, metabolic hormones, and homocysteine (Hcys) levels in children and adolescents on antipsychotics (AP) during a year-long follow-up. 117 patients, AP-naïve or quasi-naïve (less than 30 days on AP), were included. Weight, body mass index (BMI), BMI z-score (z-BMI), and levels of leptin, insulin, insulin resistance (HOMA-IR), adiponectin, ghrelin, thyroid stimulating hormone (TSH), free thyroxine (FT4), and Hcys were measured at baseline, and at 3, 6, and 12 months, while patients remained on the same AP...
May 21, 2016: European Child & Adolescent Psychiatry
https://www.readbyqxmd.com/read/27174656/non-invasive-intranasal-delivery-of-quetiapine-fumarate-loaded-microemulsion-for-brain-targeting-formulation-physicochemical-and-pharmacokinetic-consideration
#10
Brijesh Shah, Dignesh Khunt, Manju Misra, Harish Padh
Systemic drug delivery in schizophrenia is a major challenge due to presence of obstacles like, blood-brain barrier and P-glycoprotein, which prohibit entry of drugs into the brain. Quetiapine fumarate (QF), a substrate to P-glycoprotein under goes extensive first pass metabolism leading to limited absorption thus necessitating frequent oral administration. The aim of this study was to develop QF based microemulsion (ME) with and without chitosan (CH) to investigate its potential use in improving the bioavailability and brain targeting efficiency following non-invasive intranasal administration...
August 25, 2016: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/27080462/protective-effects-of-quetiapine-on-metabolic-and-inflammatory-abnormalities-in-schizophrenic-patients-during-exacerbated-stage
#11
Yu-Chen Kao, Chih-Yuan Ko, Sheng-Chiang Wang, Yia-Ping Liu
Inflammation has been considered important in the pathogenesis of schizophrenia. Increasing evidence reveals that patients with schizophrenia have abnormal expression of cytokines, which are related to development of metabolic abnormalities. Metabolic abnormality has become a critical issue, though its longitudinal relationship with the disorder, such as the antipsychotics influence, is unclear. We aimed to investigate whether abnormalities of metabolic parameters and cytokine levels in acute exacerbated schizophrenic patients existed, and whether intervention of antipsychotic could help...
April 30, 2016: Chinese Journal of Physiology
https://www.readbyqxmd.com/read/27036122/lurasidone-an-antipsychotic-with-antidepressant-effects-in-bipolar-depression
#12
Nicholas A Keks, Judy Hope, David Castle
OBJECTIVE: Lurasidone is a new serotonin-dopamine antagonist atypical antipsychotic which also appears to be effective in bipolar depression. This paper will briefly review the evidence concerning lurasidone. CONCLUSIONS: Lurasidone is an antagonist at dopamine D2, serotonin 5-HT2 and 5-HT7, and partial agonist at 5HT1a receptors; it has no anticholinergic or antihistaminic activity. Rapidly absorbed, it has a half-life of 18 ± 7 hours, will reach steady state in five days and is taken at night with food (absorption is halved on an empty stomach)...
June 2016: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/27009289/prevalence-of-antidiabetic-and-antilipidemic-medications-in-children-and-adolescents-treated-with-atypical-antipsychotics-in-a-virginia-medicaid-population
#13
Della Varghese, Cynthia K Kirkwood, Norman V Carroll
BACKGROUND: Atypical antipsychotic use among children and adolescents is a cause for concern secondary to metabolic adverse effects. There have been reports of weight gain, metabolic syndrome, dyslipidemia, glucose abnormalities, and decreased insulin sensitivity in children aged 4 to 19 years using atypical antipsychotics. OBJECTIVE: To determine the prevalence of antidiabetic and antilipidemic medication use among children and adolescents receiving atypical antipsychotics and to evaluate whether the odds of receiving antidiabetic and antilipidemic medication differs among atypical antipsychotic agents...
June 2016: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/26970936/-potentiation-strategies
#14
REVIEW
Olivier Doumy, Djamila Bennabi, Wissam El-Hage, Najib Allaïli, Rémy Bation, Frank Bellivier, Jérôme Holtzmann, Maxime Bubrovszky, Vincent Camus, Thomas Charpeaud, Pierre Courvoisier, Thierry d'Amato, Marion Garnier, Frédéric Haesebaert, Thierry Bougerol, Christophe Lançon, Fanny Moliere, Isabel Nieto, Raphaëlle Richieri, Ghassen Saba, Philippe Courtet, Guillaume Vaiva, Marion Leboyer, Pierre-Michel Llorca, Bruno Aouizerate, Emmanuel Haffen
Lithium is among the most classically recommended add-on therapeutic strategy for the management of depressive patients showing unsuccessful response to standard antidepressant medications. The effectiveness of the add-on strategy with lithium requires achieving plasma levels above 0.5 mEq/L. Mood-stabilizing antiepileptic drugs such as carbamazepine, valproate derivatives or lamotrigine have not demonstrated conclusive therapeutic effects for the management of depressive patients showing unsuccessful response to standard antidepressant medications...
March 2016: La Presse Médicale
https://www.readbyqxmd.com/read/26921085/drug-interactions-with-aprepitant-or-fosaprepitant-review-of-literature-and-implications-for-clinical-practice
#15
Anna Dushenkov, Julie Kalabalik, Antonia Carbone, Paiboon Jungsuwadee
PURPOSE: Aprepitant and its parenteral formulation fosaprepitant are widely used for the prevention of chemotherapy-induced nausea and vomiting. Aprepitant exerts modest inhibitory effect on CYP3A4 and modest inductive effect on CYP2C9 substrates such as some antineoplastics and multiple other medications. This article is aimed to provide pharmacists and other healthcare professionals with an updated summary of drug-drug interactions of aprepitant/fosaprepitant and implications for clinical practice...
February 25, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26878495/assessing-drug-drug-interactions-through-therapeutic-drug-monitoring-when-administering-oral-second-generation-antipsychotics
#16
Edoardo Spina, Christoph Hiemke, Jose de Leon
INTRODUCTION: Second-generation antipsychotics (SGAs) are frequently co-prescribed with drug metabolic inducers and inhibitors. SGA pharmacokinetic drug-drug interactions (DDIs) with inducers and inhibitors have not received enough attention in the literature but can be studied in by using therapeutic drug monitoring (TDM). AREAS COVERED: The limited information available on oral SGA pharmacokinetic DDIs is reviewed. A systematic literature search on the available oral SGA TDM studies is completed...
2016: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/26813985/quetiapine-safety-in-older-adults-a-systematic-literature-review
#17
REVIEW
N El-Saifi, W Moyle, C Jones, H Tuffaha
WHAT IS KNOWN AND OBJECTIVE: Quetiapine is a second-generation antipsychotic that is commonly prescribed for a range of approved and off-label indications in older adults. However, little is known about its safety in this population. The available evidence on quetiapine safety is based on studies on second-generation antipsychotics as a group, often in the general population and for approved indications. There are no systematic reviews on the safety of quetiapine in older adults, and therefore, there is a need for systematically assessing quetiapine safety in this group of patients to establish an appropriate safety profile for this vulnerable population...
February 2016: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/26793482/quetiapine-induced-priapism-requiring-frequent-emergency-admissions-a-case-report
#18
Jon C Jackson, Chasity L Torrence
Priapism, a rare but well-known adverse reaction of first and second generation anti-psychotics, has been hypothesized to be associated with blockade of alpha 1 receptors. However, genetic abnormalities or heritability of affected cytochrome P450 alleles has not been ruled out as a causal mechanism. A case is presented with three episodes of priapism within 17 days while taking standard FDA (Food and Drug Administration) approved doses of quetiapine. Cytochrome P450 3A4 genotype testing was performed and resulted with normal enzymatic activity...
January 2015: Urology Case Reports
https://www.readbyqxmd.com/read/26720191/increased-risk-of-obesity-and-metabolic-dysregulation-following-12-months-of-second-generation-antipsychotic-treatment-in-children-a-prospective-cohort-study
#19
Rebecca Ronsley, Duc Nguyen, Jana Davidson, Constadina Panagiotopoulos
OBJECTIVE: To determine the risk of developing obesity and related metabolic complications in children following long-term treatment with risperidone or quetiapine. METHODS: This was a 1-year naturalistic longitudinal study conducted between February 2009 and March 2012. A total of 130 children aged 2 to 18 years without prior exposure to second-generation antipsychotics (SGAs) were enrolled at initiation of treatment with either risperidone or quetiapine. Metabolic parameters were measured at baseline and months 6 and 12...
October 2015: Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie
https://www.readbyqxmd.com/read/26683988/pre-clinical-investigation-of-the-modulation-of-quetiapine-plasma-pharmacokinetics-and-tissues-biodistribution-by-lipid-core-nanocapsules
#20
Fernando Carreño, Karina Paese, Carolina Miranda Silva, Sílvia S Guterres, Teresa Dalla Costa
This study aims to investigate the changes in plasma pharmacokinetics and liver and brain distribution of quetiapine (QTP) due to its encapsulation into a polymeric nanocarrier. For this reason a bioanalytical method was developed and validated in order to quantify QTP in plasma, liver and brain tissue samples. The method was linear over the concentration range of 0.025-3.0μg.mL (r(2)>0.98), accurate, precise (R.S.D<±15%) and the recoveries, stability and validation parameters are within the acceptable limits determined by international guidelines...
February 5, 2016: Journal of Pharmaceutical and Biomedical Analysis
keyword
keyword
119251
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"